Revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Traws Pharma, Inc. (TRAW)
Price$0.5501Cached quote
Net income
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2011
2012
2013
2014
2019
2020
2023
2024
2025
Total cash / debt
CashTotal debt
2011
2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $226,000 | $226,000 | $226,000 | $226,000 | $231,000 | $2.2M | $1.2M | $787,000 | $5.5M | $11.5M | $800,000 | $4.8M | $46.2M | $1.5M |
| Research & development | $12.1M | $12.8M | $11.4M | $11.4M | $7.3M | $16.9M | $15.5M | $16.9M | $19.1M | $20.1M | $25.9M | $49.4M | $50.2M | $52.8M | $22.6M |
| Operating expenses | $20.7M | $142.6M | $20.5M | $19.9M | $16.7M | $25.2M | $23.9M | $24.5M | $26.5M | $29.2M | $35.4M | $64.5M | $67.0M | $68.5M | $29.1M |
| Operating income | −$17.9M | −$142.4M | −$20.3M | −$19.6M | −$16.5M | −$25.0M | −$21.7M | −$23.3M | −$25.7M | −$23.7M | −$24.0M | −$63.7M | −$62.2M | −$22.3M | −$27.6M |
| Operating margin | −640.68% | −62,997.35% | −8,981.42% | −8,684.51% | −7,299.12% | −10,819.48% | −994.00% | −1,895.93% | −3,270.27% | −427.39% | −209.25% | −7,968.00% | −1,309.11% | −48.23% | −1,854.27% |
| EBITDA | −$17.8M | −$142.4M | −$20.3M | −$19.6M | −$16.5M | −$25.0M | −$21.7M | −$23.2M | −$25.6M | −$23.6M | −$23.8M | −$63.3M | −$61.8M | −$22.0M | −$27.3M |
| EBITDA margin | −638.49% | −62,992.04% | −8,974.34% | −8,678.32% | −7,292.92% | −10,813.85% | −993.36% | −1,891.45% | −3,259.09% | −425.66% | −207.94% | −7,913.75% | −1,299.73% | −47.54% | −1,833.02% |
| Net income | $9.2M | −$166.5M | −$18.9M | −$19.0M | −$16.2M | −$25.2M | −$21.5M | −$20.6M | −$24.1M | −$19.7M | −$24.0M | −$63.7M | −$62.5M | −$29.9M | −$26.3M |
| Net profit margin | 328.67% | −73,682.74% | −8,384.07% | −8,391.15% | −7,151.77% | −10,890.48% | −985.02% | −1,675.33% | −3,061.25% | −354.62% | −209.31% | −7,960.25% | −1,315.86% | −64.76% | −1,768.26% |
| Basic EPSper basic share | $0.83 | -$35.21 | -$22.57 | -$22.75 | -$24.00 | -$54.25 | -$8,339.55 | -$27,929.10 | -$224,720.15 | -$5,560,819.50 | -$13,200,684.13 | -$36,821,642.64 | -$76,649,133.66 | -$192,249,052.57 | -$177,595,541.73 |
| Diluted EPSper diluted share | $0.82 | -$35.21 | -$22.57 | -$22.75 | -$24.00 | -$54.25 | -$8,339.55 | -$27,929.10 | -$224,720.15 | -$5,560,819.50 | -$13,200,684.13 | -$36,821,642.64 | -$76,649,133.66 | -$192,249,052.57 | -$177,595,541.73 |
Owners
Reported shareholders
7.88%of listed shares
ORBIMED ADVISORS LLC1.2M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
ORBIMED ADVISORS LLC | 7.88%1.2M shares |
Ally Bridge Group (NY) LLC | 5.15%786.24K shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.78%730K shares |
ADAR1 Capital Management, LLC | 3.92%597.73K shares |
Lynx1 Capital Management LP | 3.67%559.47K shares |
Ikarian Capital, LLC | 3.13%478.14K shares |
SPHERA FUNDS MANAGEMENT LTD. | 2.61%398.49K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 2.16%330.05K shares |
JANE STREET GROUP, LLC | 1.42%216.01K shares |
Dukes Iain D. | ≈1.12%171.13K shares |
Alyeska Investment Group, L.P. | 1.08%164.38K shares |
Savchuk Nikolay | ≈0.99%150.61K shares |
BOOTHBAY FUND MANAGEMENT, LLC | 0.88%133.94K shares |
Pauza Charles David | ≈0.76%115.97K shares |
Redfield Robert | ≈0.75%113.92K shares |
GEODE CAPITAL MANAGEMENT, LLC | 0.73%111.37K shares |
CAUTREELS WERNER | ≈0.72%109.22K shares |
HRT FINANCIAL LP | 0.60%91.22K shares |
Kynam Capital Management, LP | 0.55%84.4K shares |
Dauntless Investment Group, LLC | 0.53%80.57K shares |
Percentages use 15.26M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 16, 2026Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuyCommon Stock · indirect | 597.7K | $1.67 | $998.2K | 1.20M |
| Apr 16, 2026Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuySeries C Warrants (right to buy) · derivative · indirect | 1.79M | — | — | 1.79M |
| Apr 16, 2026Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuySeries B Warrants (right to buy) · derivative · indirect | 597.7K | — | — | 597.7K |
| Apr 16, 2026Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuySeries A Warrants (right to buy) · derivative · indirect | 597.7K | — | — | 597.7K |
| Dec 29, 2024Form 4 | OrbiMed Capital GP VIII LLC +1TenPercentOwner | BuySeries A Warrant (right to buy) · derivative · indirect | 96.3K | — | — | 96.3K |